- Raised $6M Series E, Dec 2020
- Raised $8.8M Series C, Apr 2016
- Raised $8M Series B, Feb 2014
About
Amorphical is an Israeli biotechnology company established in 2004. It specializes in developing and manufacturing unique natural-based medicines and dietary supplements with high bioavailability, focusing on improving calcium absorption and managing the body's acidity levels. The company's leading scientists have stabilized a rare natural form of calcium used by blue crayfish to create amorphous calcium carbonate (ACC), a nanometric substance. Amorphical's products aim to improve health, repair bone deficiencies, treat severe diseases, and aid body development and strengthening. Their pipeline includes therapies for hypoparathyroidism, pancreatic cancer, osteoporotic fractures, and Crohn's disease. The company is advancing a new class of nano-amorphous mineral pharmacologic agents, leveraging a proprietary, nature-inspired platform to address unmet needs in areas like pancreatic cancer, inflammatory diseases, and metabolic disorders by enhancing bioavailability and optimizing pH balance at the cellular level.
Funding history · 6 rounds · $28.3M total
Headcount over time
Q&A
- What is Amorphical's primary focus?
- Amorphical is a biotechnology company specializing in developing natural-based medicines and dietary supplements that utilize amorphous calcium carbonate to improve calcium absorption and manage body acidity levels.
- When was Amorphical founded?
- Amorphical was established in July 2004.
- What is the employee count for Amorphical?
- Amorphical has 11-50 employees.
- What was Amorphical's most recent funding round?
- Amorphical completed an F Round in January 2021, raising $6,000,000.
- What was the total amount of funding Amorphical has raised to date?
- Amorphical has raised a total of $31,200,000 across all funding rounds.
- What is the latest development regarding Amorphical's clinical trials for Crohn's disease?
- In February 2026, Amorphical announced it would present long-term data from its Phase 2 trial in Crohn's disease at the 21st Congress of ECCO.
- Has Amorphical started clinical trials for pancreatic cancer?
- Yes, in November 2025, Amorphical announced the enrollment of the first patient in its Phase 2 clinical trial for nano-amorphous mineral-based therapy in Stage IV pancreatic cancer patients.
- Who was appointed as CEO of Amorphical recently?
- In September 2025, Eden Ben was appointed as CEO of Amorphical.
- What were the interim results of Amorphical's clinical trial for Crohn's disease?
- In September 2025, Amorphical announced positive interim results from its ongoing clinical trial in Crohn's disease.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | amorphical.com |
|---|---|
| linkedin.com/company/72009079 | |
| facebook.com/amorphicure | |
| YouTube | youtube.com/channel/UCPSTPSBS2Kvojy6kliNYwzw |
Identifiers & details
| Legal name | Amorphical Ltd. |
|---|---|
| Founded | 2004-7 |
| Employees (exact) | 50 |
Radar intelligence
Patents
| EPO | 23 |
|---|
Publications (Crossref)
| Works | 4 |
|---|
Web history (Wayback)
| Domain | amorphical.com |
|---|
Certificate / subdomain footprint
| Subdomains | 22 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513562686 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2004-07-01 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 5 — charge (1), other (1), annual_report (2), shares_capital (1) |
| Registered address | 56 צופר |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-30 | רישום שעבוד |
| 2026-04-23 | שינוי בתקנון |
| 2025-11-16 | דו~ח שנתי-הוספת בעל תפקיד |
| 2025-11-16 | דו~ח שנתי-הוספת דירקטור |
| 2026-05-13 | העברת מניות |